WO2004083241A3 - Proteines interagissant avec btc et utilisation de ces proteines - Google Patents

Proteines interagissant avec btc et utilisation de ces proteines Download PDF

Info

Publication number
WO2004083241A3
WO2004083241A3 PCT/JP2004/003699 JP2004003699W WO2004083241A3 WO 2004083241 A3 WO2004083241 A3 WO 2004083241A3 JP 2004003699 W JP2004003699 W JP 2004003699W WO 2004083241 A3 WO2004083241 A3 WO 2004083241A3
Authority
WO
WIPO (PCT)
Prior art keywords
btc
protein complexes
interacting proteins
disorders
diseases
Prior art date
Application number
PCT/JP2004/003699
Other languages
English (en)
Other versions
WO2004083241A2 (fr
Inventor
Takeshi Sakamoto
Shizu Takeda
Original Assignee
Takeda Pharmaceutical
Takeshi Sakamoto
Shizu Takeda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical, Takeshi Sakamoto, Shizu Takeda filed Critical Takeda Pharmaceutical
Publication of WO2004083241A2 publication Critical patent/WO2004083241A2/fr
Publication of WO2004083241A3 publication Critical patent/WO2004083241A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des complexes protéiques contenant BTC et une ou plusieurs protéines sélectionnées dans le groupe constitué par GROUP1. Cette invention concerne également des méthodes d'utilisation de ces complexes protéiques dans le diagnostic de maladies et de troubles. En outre, lesdits complexes protéiques sont également utiles dans des méthodes de criblage permettant d'identifier des composés efficaces dans le traitement et/ou la prévention de maladies et de troubles associés à BTC et ses interacteurs.
PCT/JP2004/003699 2003-03-19 2004-03-18 Proteines interagissant avec btc et utilisation de ces proteines WO2004083241A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45600703P 2003-03-19 2003-03-19
US60/456,007 2003-03-19
US45994403P 2003-04-02 2003-04-02
US60/459,944 2003-04-02

Publications (2)

Publication Number Publication Date
WO2004083241A2 WO2004083241A2 (fr) 2004-09-30
WO2004083241A3 true WO2004083241A3 (fr) 2005-03-31

Family

ID=33032708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/003699 WO2004083241A2 (fr) 2003-03-19 2004-03-18 Proteines interagissant avec btc et utilisation de ces proteines

Country Status (1)

Country Link
WO (1) WO2004083241A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100960256B1 (ko) 2001-02-27 2010-06-01 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
ES2683021T3 (es) 2008-07-28 2018-09-24 Blanchette Rockefeller Neurosciences Institute Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas
EP2326729B1 (fr) 2008-07-28 2015-04-22 Blanchette Rockefeller Neurosciences, Institute Marqueurs de profil génomique induits par un stimulus, marquant la maladie d'alzheimer
EP2483684B1 (fr) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Motifs de croissance de fibroblastes pour le diagnostic de la maladie d'alzheimer
WO2013071281A1 (fr) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters de dcpla et méthodes de traitement les utilisant
CA2880649C (fr) 2012-08-01 2023-03-14 Elizabeth MCNALLY Reduction des lesions tissulaires et de la fibrose via la proteine-4 de liaison au tgf beta latent (ltbp4)
FR3061179A1 (fr) * 2016-12-22 2018-06-29 Universite Toulouse Iii-Paul Sabatier Peptides therapeutiques
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARTEL P L ET AL: "ANALYZING PROTEIN-PROTEIN INTERACTIONS USING TWO-HYBRID SYSTEM", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 254, 1995, pages 241 - 263, XP001013374, ISSN: 0076-6879 *
DATABASE EMBL [online] 1 June 2003 (2003-06-01), STRAUSBERG ET AL.: "Protein similar to prickle-like 1", XP002284782, Database accession no. Q80Y24 *
DUNBAR ANDREW J ET AL: "Structure-function and biological role of betacellulin", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 32, no. 8, August 2000 (2000-08-01), pages 805 - 815, XP002284781, ISSN: 1357-2725 *
KATOH MASUKO ET AL: "Identification and characterization of human PRICKLE1 and PRICKLE2 genes as well as mouse Prickle1 and Prickle2 genes homologous to Drosophila tissue polarity gene prickle.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 11, no. 2, February 2003 (2003-02-01), pages 249 - 256, XP009032404, ISSN: 1107-3756 (ISSN print) *

Also Published As

Publication number Publication date
WO2004083241A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2004074455A3 (fr) Variants de la region fc
WO2006038208A3 (fr) Agents capable de reguler a la baisse un hif-1$g(a) dependant de msf-a et utilisation de ceux-ci pour traiter un cancer
WO2006055689A3 (fr) Squelettes proteiques et leurs utilisations
WO2005051178A3 (fr) Marqueur pour la neuromyelite optique
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
WO2004007743A3 (fr) Utilisation d'acides nucleiques cpg dans les maladies a prions
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
WO2004062475A3 (fr) Dosages fluorescents de proteines kinases
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2001072822A3 (fr) Genes impliques dans les maladies inflammatoires de l"intestin et leur utilisation
AU2003234198A1 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
WO2003005880A3 (fr) Les peptides 'replikines' et leurs utilisations
WO2005000876A3 (fr) Proteines de la famille des proteines a doigts de zinc (ring finger) et leurs utilisations
WO2004110365A3 (fr) Compositions et methodes destinees au traitement de maladies hepatiques
WO2003027251A3 (fr) Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation
WO2002073212A3 (fr) Analyses diagnostiques destinees a la maladie d'alzheimer
WO2001085980A3 (fr) Tests enzymatiques destines au criblage d'agents anticancereux
EP2292666A3 (fr) Anticorps specifiques des neoplasmes et leurs utilisations
IL159479A0 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2004070012A3 (fr) Molecules d'elimination de cellules et methodes d'utilisation associees
WO2004005351A3 (fr) Anticorps specifiques de neoplasme et utilisations associees
WO2003087051A3 (fr) Procedes d'identification de sites allosteriques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase